PHARNasdaqPharmaceutical PreparationsFiscal year ends December 31

Pharming Group N.V.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 2, 2026

$9.11−0.25 (-2.67%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): 2277.5
Dividend yield: –

Pharming Group N.V. income statement

AnnualQuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Revenue	376	297	245	206	199	212	189	–
Cost of Revenue	46	35	25	18	21	24	24	–
Gross Profit	331	262	220	188	178	189	165	–
Research & Development	100	83	69	53	70	39	32	–
Selling & Marketing	131	119	124	86	59	52	45	–
Operating Income	26	-8.62	-5.39	18	14	76	68	–
Interest Expense	0.20	0.06	0.13	0.11	0.09	0.07	0	–
Income from Equity Investments	0.62	-1.76	-0.29	-1.08	0.69	0.36	0.26	–
Pretax Income	13	-8.49	-12	15	23	44	52	–
Income Tax Expense	10	3.35	-1.46	1.31	7.08	6.35	12	–
Net Income incl. Noncontrolling Interests	2.54	-12	-11	14	16	38	41	–
Minority Interest in Earnings	-0.31	0	0	–	–	–	–	–
Net Income	2.85	-12	-11	–	–	–	–	–
EPS (Basic)(per share)	0.0040	-0.02	-0.02	0.02	0.03	0.06	0.07	–
EPS (Diluted)(per share)	0.0040	-0.02	-0.02	0.02	0.02	0.06	0.06	–
Shares Outstanding (Basic, Weighted)(shares)	689	671	657	649	642	636	626	607
Shares Outstanding (Diluted, Weighted)(shares)	747	785	725	707	701	683	674	654
EBITDA	–	–	–	–	20	82	73	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Dec 31, 2025

Profitability, FY2025

Gross margin: 87.9%
Operating margin: 6.9%
Net margin: 0.8%
Return on equity, FY2025: –

Financial strength

Current ratio: 2.59
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 125.5%

Valuation

P/E ratio: 2277.5
Price to sales: –
Price to book: –
Dividend yield: –